Cidara Therapeutics, Inc.
CDTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $170,678 | $69,417 | $52,847 | $66,584 |
| - Cash | $189,825 | $35,778 | $32,731 | $62,273 |
| + Debt | $3,576 | $4,877 | $1,211 | $5,061 |
| Enterprise Value | -$15,571 | $38,516 | $21,327 | $9,372 |
| Revenue | $1,275 | $23,283 | $64,448 | $49,572 |
| % Growth | -94.5% | -63.9% | 30% | – |
| Gross Profit | $1,275 | -$13,480 | $64,448 | -$23,515 |
| % Margin | 100% | -57.9% | 100% | -47.4% |
| EBITDA | -$175,869 | -$26,948 | -$33,360 | -$42,066 |
| % Margin | -13,793.6% | -115.7% | -51.8% | -84.9% |
| Net Income | -$169,827 | -$22,931 | -$33,584 | -$42,467 |
| % Margin | -13,319.8% | -98.5% | -52.1% | -85.7% |
| EPS Diluted | -26.75 | -5.25 | -9.61 | -16.19 |
| % Growth | -409.5% | 45.4% | 40.6% | – |
| Operating Cash Flow | -$176,533 | -$22,432 | -$28,473 | -$25,232 |
| Capital Expenditures | -$129 | -$505 | -$118 | -$41 |
| Free Cash Flow | -$176,662 | -$22,937 | -$28,591 | -$25,273 |